

#### Management of Fibroids with Leuprolide Acetate

ROMANO NKUMBWA BYARUHANGA

MB.CH.B, M.MED OBS/GYNAE, PHD, FCOG(ECSA)



### Outline

Definition

Epidemiology

Pathophysiology

Signs and Symptoms

Management Option

### Uterine Fibroids

- Monoclonal benign tumors that arise from the uterine smooth muscle tissue
- Composed of disordered myofibroblasts buried in abundant quantities of extracellular matrix
- Increased Estrogen and progesterone receptors compared to surrounding myometrium
- ➤ Prevalence:16.7% 30% of reproductive-age
- ➤ By the age of 50 years 70-80% of women will have at least one fibroid
- ▶It is more common in African-descent
- >20-50% are symptomatic

SOGC 2015/Eduard et al 2024





### Etiology and Risk factors

- Exact aetiology not known
- Monoclonal origin ( arising from a single cell)

#### Genetic basis definite-

- ➤ 40%-(translocation chromosome 12/14, rearrangement of short arm Ch6, rearrangement of long arm Ch10, deletion at Ch3, Ch. 7q, trisomy 12)
- Various growth factors like TGFβ, EGF, IGF-1, IGF-2, and BFGF are recently implicated in the development of fibroids.

#### **Hormonal dependence:**

estrogen may contribute to tumor enlargement by increasing the production of extracellular matrix. While Progesterone increases Mitotic activity

- > Early menarche
- ➤ Null parity
- ➤ Age (Older women > younger age)
- > African descent
- Family history of Fibroids
- **≻**Obesity

#### Factors that lower the risk for fibroids


- Pregnancy
- Low-term use of COC or injectable contraceptive

Stewart E.A et al BJOG 2017



### FIGO SUBCLASSIFICATION

Leiomyoma Subclassification System



S – Submusosal	0	Pedunculated intracavitary
	1	< 50% intramural
	2	≥ 50% intramural
O – Other	3	Contacts endometrium; 100% intramural
	4	Intramural
	5	Subserosal ≥ 50% intramural
	6	Subserosal < 50% intramural
	7	Subserosal pedunculated
	8	Other (specify e.g. cervical, parasitic)

Hybrid leiomyomas (impact both endometrium and serosa)	Two numbers are listed separated by a hyphen. By convention, the first refers to the relationship with the endometrium while the second refers to the relationship to the serosa.  One example is below		
	2-5	Submusocal and subserosal, each with less than half the diameter in the endometrial and peritoneal cavities, respectively.	



### Pathology of Fibroids



#### **Gross Appearance:**

Multiple, discrete, spherical, pinkish-white, firm capsulated masses protruding from the surrounding myometrium. Pseudo capsule is made up of compressed myometrium giving it a distinct outline

#### Microscopy-

- Non-striated muscle fibres are arranged in interlacing bundles of varying size & running in different directions (whorled appearance).
- Varying amounts of connective tissue is intermixed with smooth muscle fibres

**Secondary changes-** Hyaline, calcific, necrosis, red degeneration during pregnancy, fatty degeneration

**Leiomyosarcoma-** 0.49-0.79%, more common in the 5<sup>th</sup> decade, diagnosed with the presence of mitotic figures



### Fibroids and symptoms

Fibroids growth is influence by oestrogen and progesterone levels.

The biologically potent estrogen estradiol induces the production of PR by means of ER- $\alpha$ .PR is essential for the response of fibroid tissue to progesterone secreted by the ovaries

- ➤ Heavy or prolonged menstrual periods with associated anemia
- >Abnormal uterine bleeding -.
- ➤ Pelvic pain
- Obstructive symptoms
- **→**Torsion
- **>** Infertility



# Effects in pregnancy

- **>** Abortions
- ➤ Pressure symptoms and Abdominal pain
- ➤ Malpresentation
- ► Preterm Labour
- ➤ Dystocia in Labour
- **PPPH**
- > Poor sub involution
- > Puerperal sepsis



#### Treatment

#### Individualized based on


- >Symptomatology,
- **≻**Size
- ► Location of fibroids
- **≻**Age
- Experience of the therapist.

#### Medical

- ➤ Non-steroidal anti-inflammatory drugs
- ➤ Levonorgestrel Intrauterine device
- **≻**GnRH agonists
- Ulipristal
- ▶ Danazole
- ➤ Oral contraceptives
- ➤ Uterine artery embolization
- ➤ Myolysis
- ➤ Magnetic Resonance focused scan

#### Surgical

- **≻**Myomectomy
- > Hysterectomy






Leuprolide acetate 3.75 mgs sc for 3 months

#### **Effect**

Produce profound hypoestrogenism



(1 month Depot) Lyophilized

For Intramuscular / Subcutaneous use For Single use only Not for Intravenous Administration





Manufactured in India by :

BHARAT SERUMS AND VACCINES LIMITED

Plot No. K-27, Additional M.I.D.C., Ambernath (E) - 421 501

### GnRH analogues

Gonadotrophin releasing hormone (GnRH) analogues are synthetic drugs (decapeptide) modeled like natural human hypothalamic Gonadotrophin releasing hormone.

#### **GNRH** agonists and Antagonists


Substitution of an amino acid at the 6 or 10 position results in analogues with agonistic activity.

Modification at the 2 or 3 position results in analogues with antagonistic properties.


The deletion of an amino acid at the 10 position also increases the binding affinity of analogues

# GnRH analogues


#### **Structure of GnRH**



# Action of GnRH agonists



## Action of GnRH antagonists



# MOA of GNRH agonists & antagonists

#### **GNRH AGONISTS**

Repeated administration of an agonist in a continuous manner results in pituitary GnRH receptor downregulation, gonadotropin secretion of FSH, LH, and decreased steroidogenesis and gametogenesis.

#### **GNRH ANTAGONISTS**

Cause immediate, rapid gonadotropin suppression by **competitively** blocking GnRH receptors in the anterior pituitary gland, thereby preventing endogenous GnRH from inducing LH and follicle-stimulating hormone (FSH) release from the pituitary cells

6/28/2024 16

### Pre-Operative treatment with Leuprolid



Significant shrinkage of uterine fibroids-30%- 40%

Reduces vascularity

Drop in uterine volume-40% - 60%

Hemoglobin levels increased (Cessation of Menstruation)

Intra-operative blood loss significantly lower

Hence fewer blood transfusions

6/28/2024 17

### Surgical Management



#### Myomectomy



Hysterectomy

**Abdominal** 

Vaginal

Hysteroscopy

Laparoscopic

Abdominal Vaginal LAVH




#### GnRH agonists

#### **Goal in treatment**

- Decrease Size of Fibroids
- Decrease Bleeding during surgery

40-60 % decrease in mean uterine volume if given over a 3 months period



# Other Medical pharmaceutical Drug options

#### ➤ GnRH antagonists – Oral

Elagolix oral: 300mgs bid (with add back)

Relugolix /estradiol/Norethindrone combination – ( 40mgs /1mg/0.5mg) oral once daily

Linzagolix 100-200mgs daily

➤ Ulipristal Acetate 5mgs daily -

➤ Levonogestrol intrauterine Contraceptive device — Mirena


### Uterine artery embolization



- By interventional radiologist
- Catheter is passed retrograde through Right femoral artery to bifurcation of aorta & then negotiated down to opposite uterine artery first.
- ➤ Polyvinyl alcohol (PVA) particles (500-700 um) or gelfoam are used for embolization.
- >60 65 % reduction in size of fibroid
- >80 90 % have improvements in menorrhagia & pressure symptoms

### Uterine artery embolization






A catheter is inserted through a small incision in the skin into an artery and advanced to the uterus.

6/28/2024 22

### Newer Management-MRGFUS



- ► Permitted by FDA since 2004
- MRI guidance is used to direct ultrasound to tissues to elicit coagulative necrosis via thermal ablation.



6/28/2024 23



### THANK YOU AND QUESTIONS